ENDORSED TRIALS

Clinical Trials

Endorsed Trials

Title: MERIT – MEtformin for treating PAD Related walking Impairment Trial Partnership

Status: Seed funding

Summary: This is a placebo-controlled randomised trial performed across multiple Aisytralian sites. Participants with intermittent claudication, but no diabetes, will be randomised to metformin or placebo daily and followed for six months. The primary outcome is the change in six-minute walk test (6MWT) distance over six months.

Chief Investigator:  Prof John Golledge – jonathan.golledge@jcu.edu.au 

For more information contact: Alkira Vann, Clinical Trials Coordinator – alkira.venn@jcu.edu.au 

Title: IDEAL Partnership – Improved cardiovascular Disease hEALth service delivery in Australia

Status: Funded

Summary: The IDEAL study aims to improve the way doctors manage patients’ risk of cardiovascular disease, including conditions such as heart attack or stroke. This research focuses on the development of a new service to calculate cardiovascular risk and deliver this information to GPs to help them make well-informed treatment decisions around risk management to improve outcomes for their patients.

Chief Investigator:  Prof James Sharman – james.sharman@utas.edu.au

For more information contact: Gudrun Wells – gudrun.wells@utas.edu.au 

Title: Metformin Aneurysm Trial 

Status: Funded

Summary: Metformin Aneurysm Trial is a multicentre, randomised, placebo-controlled trial to assess if 1500 mg of metformin per day will reduce Abdominal Aortic Aneurysm (AAA)-related events in patients with small AAAs who do not have diabetes.

Chief Investigator:  Prof Jon Golledge – jonathan.golledge@jcu.edu.au

For more information contact: Sophie Rowbotham, Global Trial Manager – sophie.rowbotham@jcu.edu.au

Title: COLCARDIO-ACS –  Cardiovascular Outcomes in Acute Coronary Syndrome trial

Status: Funded

Summary: The aim of this trial is to assess the effect of colchicine (0.5 mg/day) in addition to optimal medical therapy on cardiovascular outcomes in ACS patients with evidence of persistent coronary inflammation (based on hsCRP). We hypothesise that addition of colchicine to optimal medical therapy in patients post-ACS, who have biomarker evidence of persistent inflammation will reduce recurrent cardiovascular events.

Chief Investigator: Prof Tony Keech – tony@ctc.usyd.edu.au

For more information contact: Annie Yeung, Project Manager – colcardio-acs@ctc.usyd.edu.au

Title: EASY-AS – The Early valve replacement in severe ASYmptomatic Aortic Stenosis trial

Status: Funded

Summary: In a large collaborative trial, the researchers in Australia will work with colleagues in the United Kingdom and in New Zealand to test the best strategy by randomising 2,844 patients with severe, asymptomatic aortic stenosis. They will either undergo early valve replacement or a conventional approach of regular close follow-up, with surgery recommended if and when symptoms develop.

Chief Investigator:  Prof Graham Hillis – Graham.Hillis@health.wa.gov.au

For more information contact: Tom Gilbert, Project Manager –  thomas.gilbert@uwa.edu.au

Title: QUEL – QUality improvement in primary care to prevent hospitalisations and improve Effectiveness and efficiency of care for people Living with coronary heart disease.

Status: Funded

Summary: The aim of this study is to determine if a practice-level collaborative quality improvement program, focused on patients with coronary heart disease (CHD), reduces the rate of unplanned cardiovascular (CVD) hospitalisations and major adverse CVD events, and increases the proportion of patients achieving risk factor targets at 24 months.

Chief Investigator:  Prof Julie Redfern – julie.redfern@sydney.edu.au

For more information contact: Qiang (Tony) Tu, Research Officer –  qiang.tu@sydney.edu.aus

Contact us

© ANZACT All Rights Reserved